Literature DB >> 7669568

Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity.

A M Pullyblank1, P J Guillou, J R Monson.   

Abstract

Antibodies are thought to bring about tumour cell lysis by antibody-dependent cell-mediated cytotoxicity (ADCC), but the exact mechanism is not well elucidated. Monocytes are known to be important mediators of anti-tumour ADCC and are also known to secrete the cytokines tumour necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1 beta), both of which have been shown to bring about tumour cell lysis. We examined the release of these cytokines during ADCC and attempted to elucidate which components of the ADCC reaction were necessary for cytokine production. We measured TNF-alpha and IL-1 beta in supernatants collected from a standard ADCC assay using each of the anti-colorectal antibodies m17-1A, c17-1A and cSF25. We found that there was significant TNF-alpha and IL-1 beta release during ADCC mediated by each of these three antibodies and that the magnitude of cytokine release seemed to reflect the degree of tumour cell lysis produced by each antibody. Furthermore, we found that effector cells, target cells and a specific anti-tumour antibody were necessary for this to occur. The presence of only some of the components of the reaction or of an irrelevant antibody produced little or no TNF-alpha or IL-1 beta. We conclude that TNF-alpha and IL-1 beta are released when an effector and tumour target cell are united by a specific tumour antibody and that these cytokines may be important in bringing about tumour cell lysis during the ADCC reaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669568      PMCID: PMC2033875          DOI: 10.1038/bjc.1995.380

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  The mechanisms of antibody-dependent killing mediated by lymphoid and myeloid cells are distinct based on different divalent cation requirements.

Authors:  R F Graziano; D V Erbe; M W Fanger
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

2.  In vivo localization of human colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen.

Authors:  H Takahashi; B Wilson; M Ozturk; P Motté; W Strauss; K J Isselbacher; J R Wands
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

3.  LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release.

Authors:  D S Webb; Y Shimizu; G A Van Seventer; S Shaw; T L Gerrard
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

4.  Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor.

Authors:  B Luettig; T Decker; M L Lohmann-Matthes
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

5.  Radioimmunolocation of hepatic and pulmonary metastasis of human colon adenocarcinoma.

Authors:  H Takahashi; R Carlson; M Ozturk; S Sun; P Motte; W Strauss; K J Isselbacher; J R Wands; D Shouval
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

6.  Coordinated induction of autocrine tumor necrosis factor and interleukin 1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity.

Authors:  D M Smith; G A Lackides; L B Epstein
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

7.  Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis.

Authors:  R Jänicke; D N Männel
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

8.  Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages.

Authors:  K M Wilson; G Siegal; E M Lord
Journal:  Cell Immunol       Date:  1989-10-01       Impact factor: 4.868

9.  Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.

Authors:  J H Qian; J A Titus; S M Andrew; D Mezzanzanica; M A Garrido; J R Wunderlich; D M Segal
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

10.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

View more
  6 in total

1.  Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

Authors:  E Jensen-Jarolim; J Singer
Journal:  Clin Exp Allergy       Date:  2011-05-05       Impact factor: 5.018

2.  Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.

Authors:  Q Zhou; A Gil-Krzewska; G Peruzzi; F Borrego
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

3.  Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.

Authors:  A G Heriot; J B Marriott; S Cookson; D Kumar; A G Dalgleish
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

4.  Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.

Authors:  Madelyn Espinosa-Cotton; Samuel N Rodman Iii; Kathleen A Ross; Isaac J Jensen; Kenley Sangodeyi-Miller; Ayana J McLaren; Rachel A Dahl; Katherine N Gibson-Corley; Adam T Koch; Yang-Xin Fu; Vladimir P Badovinac; Douglas Laux; Balaji Narasimhan; Andrean L Simons
Journal:  J Immunother Cancer       Date:  2019-03-19       Impact factor: 13.751

5.  A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Authors:  Madelyn Espinosa-Cotton; Elana J Fertig; Laura P Stabile; Autumn Gaither-Davis; Julie E Bauman; Sandra Schmitz; Katherine N Gibson-Corley; Yinwen Cheng; Isaac J Jensen; Vladimir P Badovinac; Douglas Laux; Andrean L Simons
Journal:  Biomark Res       Date:  2019-07-16

6.  Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.

Authors:  Louise Saul; Debra H Josephs; Keith Cutler; Andrew Bradwell; Panagiotis Karagiannis; Chris Selkirk; Hannah J Gould; Paul Jones; James F Spicer; Sophia N Karagiannis
Journal:  MAbs       Date:  2014-01-14       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.